Infinity Bio

Infinity Bio, Inc. is a biotechnology company that provides detailed insights into the human immune system using its proprietary antibody reactome profiling platform called MIPSA (Mammalian Immune Profiling of Serum Antibodies). Developed at Johns Hopkins University in Dr. H. Benjamin Larman's Laboratory of Precision Immunology, the technology comprehensively analyzes the full set of antibody binding interactions against all known human viruses, human proteins, and environmental allergens. Infinity Bio serves the research, biopharma, and translational communities to enable discovery and characterization of immune-driven disease at population scale, and closed an $8M Series A in 2025 led by Illumina Ventures.